



European Partnership on Animal Health & Welfare (PAHW)

Hein Imberechts (Sciensano) & Jean-Charles Cavitte (DG-AGRI)

Presenter of today: Arnaud Callegari (Anses)

Presentation of PAHW Dossier

11 May 2022

CWG and SCAR

- **Standing Committee of Agriculture Research** and Collaborative Working Group on Animal Health and Welfare
 - Link SCAR: <https://scar-europe.org/>
 - Link CWG AH&W: <https://www.scar-cwg-ahw.org/index.php/organisation/>

Introduction to partnerships

PAHW: WHY a Partnership?



- **No single Member State** has the capacity on its own to address the challenges faced (developing new vaccines and diagnostic tools, understanding epidemiology of diseases etc.)
- **Duplication** of work among countries
- **Insufficient AH industry interest or investments** in certain domains
- **Increased need for data management**, not least for broad surveillance
- Development and ‘validation’ of products, require a **continuum in the R&I chain from low to high TRLs ...**

An ambitious partnership approach around shared priorities, rather than scattered topics in Horizon Europe work programmes

PAHW: building on existing initiatives

- **History of successful** (but relatively modest) **EU public-public research partnerships**
 - ERA-NETs: FP7 EMIDA (AH) , ANIHWA (AHW):€70mio in joint transnational calls
 - **H2020 ICRAD**: 1st call over €20mio
 - For AW: also SusAn and Core-Organic
- These were based on **SCAR CWG Animal Health and Welfare** (over 20 countries)
 - Also SCAR FISH
 - CWG AHW platform for co-designing PAHW
- **One Health European Joint Programme**, €90mio co-fund
- **International Research Consortium** (STAR-IDAZ IRC), opening new avenues for global cooperation.
- (ETP GAH and) **Discontools**



New approach to European Partnerships

Conditions for launching a partnership:

- SRIA to demonstrate partners' common strategic vision
- Ex-ante long-term commitment from partners

New generation of objective-driven and more ambitious partnerships in support of agreed EU policy objectives

Key features

- **Strategic orientation**
- **Common set of criteria for the life-cycle (Horizon Europe regulation Article 10 and Annex III)**
- **Systematic approach**
- **Simple architecture and toolbox**

Co-programmed

Based on contractual arrangement / MoU; implemented independently by the partners and by Horizon Europe

Co-funded

Based on a joint programme agreed by partners (Grant Agreement); MS/ACs design a common programme to be implemented under their responsibility.

Institutionalised

Partnerships based on Articles 185 /187 of TFEU and the EIT-Regulation supported by Horizon Europe. Implementation by a dedicated structure.

Overview of 49 candidate European Partnerships

PILLAR II - Global challenges & European industrial competitiveness

PILLAR III - Innovative Europe

CLUSTER 1: Health	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bioeconomy, Agriculture, ...	EIT	SUPPORT TO INNOVATION ECOSYSTEMS
Innovative Health Initiative	Key Digital Technologies	Clean Hydrogen	Circular Bio-based Europe	InnoEnergy	Innovative SMEs
Global Health Partnership	Smart Networks & Services	Clean Aviation	Rescuing Biodiversity to Safeguard Life on Earth	Climate	
Transformation of health systems	High Performance Computing	Single European Sky ATM Research 3	Climate Neutral, Sustainable & Productive Blue Economy	Digital	
Chemicals risk assessment	European Metrology (Art. 185)	Europe's Rail	Water4All	Food	
ERA for Health	AI-Data-Robotics	Connected and Automated Mobility (CCAM)	Animal Health & Welfare*	Health	
Rare diseases*	Photonics	Batteries	Accelerating Farming Systems Transitions*	Raw Materials	
One-Health Anti Microbial Resistance*	Made in Europe	Zero-emission waterborne transport	Agriculture of Data*	Manufacturing	
Personalised Medicine*	Clean steel – low-carbon steelmaking	Zero-emission road transport	Safe & Sustainable Food System*	Urban Mobility	
Pandemic Preparedness* <i>Co-funded or co-programmed</i>	Processes4Planet	Built4People		Cultural and Creative Industries	
	Global competitive space systems**	Clean Energy Transition			
		Driving Urban Transitions			

CROSS-PILLARS II AND III

European Open Science Cloud

- Institutionalised Partnerships (Art 185/7)
- Institutionalised partnerships / EIT
- Co-Programmed
- Co-Funded

* Calls with opening dates in 2023-24
 ** Calls with opening dates not before 2022



Co-funded European Partnership

- **Member States design a common programme** to be implemented under their responsibility. It pools national funding/resources with co-funding from the Union.
- Legal form: **Grant Agreement** (for a “programme co-fund action”) signed between a **consortium** of beneficiaries and the Commission (Executive agency for the implementation)
- EU co-funding rate **to the partnership***: 30% of eligible costs (in justified cases up to 50%**)
- **Calls for proposals are organised by the partnership** (published on EU Tenders Portal)
- Beneficiaries in selected projects are **funded at national level** (on the basis of rules agreed by partners).
- Important to **define ex-ante**:
 - **Types of partners needed** to form the partnership (consortium);
 - Stakeholders that provide strong input to **priority setting** ← **role of ministries**
 - Stakeholders and target groups addressed/ involved by the activities implemented

*: *it is up to the consortium to agree internally on how the EU co-funds is best used/distributed within the consortium*

**: *depends on centre of gravity between internal activities and activities performed through external calls*

Cash contributions

- The partnership will **need cash contributions from Member States** (in addition to the EU contribution)
- To be **used for paying the grants to the research performers** – following the partnership’s calls for proposals
- Paying these grants is called **“Providing financial support to third parties”**

In-Kind Contributions

- Any direct expenditure of a partner in the consortium (**other than providing financial support to third parties**) for activities of the partnership are, in principle, in-kind contributions
- The **coordination and management** of a partnership could be an example of such an activity
- If the **partners perform R&D themselves**, the man-hours are an in-kind contribution
- **Institutional funding of research performing or governmental organisations**, if they are implementing R&I activities in the partnership, can also qualify as in-kind contribution

The EUP AH&W content

Co-Funded EUP AH&W: the content

- **Scope**

- Animal infectious diseases, including consequences for public health; animal welfare
- Livestock (terrestrial and aquatic animals); wildlife and companion animals where relevant

- **Aim**

- Reinforce preparedness against upcoming and emerging threats for both animals and humans
- Promote and strengthen animal welfare
- Generate innovative methodologies and products
- Support evidenced based policy making
- Strengthen ERA and leverage resources in animal health and welfare



- **Impact**


- Socio-economic and environment impact of animal infectious diseases reduced
- Animal welfare improved
- Economic viability of farms protected
- Safe food and benefit for public health



Vision of the Partnership

The vision of the PAHW is to provide society with reassurance on the **control of infectious animal diseases** with appropriate means, where **antimicrobials are prudently used**, where **animal welfare** is respected and improved, thus contributing to **sustainable livestock farming** and the protection of **public health** and the **environment**.

This vision and ambition will be achieved through strengthened cooperation between **public** research and innovation entities, and the association of relevant partners, **including the animal health industry**.



AID + zoonoses
Wildlife
Bio-informatics
AMR anim. pathogens
FAIR data AH&W
Animal welfare

Research on pathogens
Direct-indirect; pen-site
DIVA, dead/alive
Multi-target
Sampling

es

Positive welfare
Slaughter technologies
Welfare at slaughter
Psychological indicators
Precision farming
AW & transport

Methodologies
Wildlife & human interventions
Genomic surveillance
Spread AMR
Emergency networks
AW surveillance

- *OO1. To design and harmonize surveillance*
- *OO2. To develop **diagnostic** procedures, and monitoring of **animal health***
- *OO3. To develop **procedures, methodologies and tools** to support **animal welfare***
- *OO4. To adapt **risk assessment and alert communication** to the new needs in **animal health and welfare***

See PAHW Dossier on EU website: [link](#)

Operational objectives

Network of experts
 Biosecurity
 Prudent use AM
 Animal resilience
 Experimental farms

Network of experts
 AW and farm sustainability
 Welfare indicators
 Feeding & breeding
 Experimental farms

fight against

Basic research (TRL1-2)
 Develop tools on farm, models, bio-informatics
 Develop & improved I&T
 Uptake by industry

- *OO5. To develop guidelines and **diseases on farm***
- *OO6. To develop guidelines and prototype **solutions that advance farm, during transport and at the end of life***
- *OO7. To develop new **interventions and treatments**, or improve existing ones, against specific priority infectious disease of animals*
- *OO8. To develop new **vaccines** or improve existing vaccines, incl. adjuvants and immune-modulators*

Study immune system
 Develop tools
 Develop & improve vaccines and immuno-modulators
 Uptake by industry

See PAHW Dossier on EU website: [link](#)


Monitor PAHW projects
Manage IP
Support regulatory process
Procedures to support clinical studies

Objectives

- **OO9. To increase access to veterinary vaccines, interventions and treatments and uptake of said vaccines interventions and treatments in the field**
- **OO10. To study socio-economic aspects and impact of infectious animal diseases (incl. AMR) and of insufficient animal welfare, and the needs and barriers to mitigate the risks**

Burden of disease
Social science studies AH and AW
Study incentives and barriers among farmers
Study the integration AH, AW and production

See PAHW Dossier on EU website: [link](#)



Proposed scenario

Research Performing Organizations, RPO

Funding Organizations, FO

Private

- Research activities performed both through (mainly) external, open calls, plus activities performed internally
- **Open R&I calls**
 - Aiming at **generating knowledge**, at **including private partners** in the research, e.g. **to bring in new technologies** for diagnostics or vaccine development etc., to facilitate uptake by industry
 - Or in case **additional expertise** is needed but not available in the partnership consortium
 - Organized by Funding Organizations (**in cash funding**; EC co-funding possible)
 - All infectious diseases, both basic and applied research
- **Internal R&I calls**
 - **Reinforce cooperation** among research centres, reference laboratories/centres, with **specific mandates** (e.g. regulated diseases and AMR; reference activities), or special experimental facilities; mainly **integrative research** (capacity building, data sharing and risk assessment); **policy driven research** (incl. animal welfare)
 - All are EC co-funded and partners contribute through **in kind funding**
- See also other activities!
- The more internal calls, the greater the chance of higher EC co-funding

Other activities (other than research calls)

- **Integrative activities focussing on the laboratories, risk assessment and risk management**
 - Shared infrastructure, shared repositories, databases
 - Capacity building: harmonization and standardization, proficiency testing, etc.
- **Other joint activities** to strengthen the consortium
 - Consultation meetings with stakeholders and interested parties
 - Education and training activities
- **Communication, dissemination and exploitation** towards a broader audience, i.e. scientists, professionals, policy makers, other stakeholders, incl. consumers and citizens; to support **uptake of outcome** and to **gain impact**
- These activities will have **to be decided by the consortium**, since some of them could also be organized in calls

The EUP AH&W organization

Under construction!

Partnership Animal Health & Welfare

General Assembly

Beneficiaries representatives

Call Boards

To oversee the Call Office

Call Office

Internal Call Office

RPO only

Governing Board

*Authorities
EC + PMT representatives*

Management Team

CT + WP Leaders

Coordination Team

*Coordinator + deputies +
Support Team*

EFSA, EMA, OIE, FAO, ...

Other EU Partnerships

Other networks & Consortia

Industry

Farmers, Vets

Universities


STAKEHOLDERS COMMITTEE

SCIENTIFIC ADVISORY BOARD

National Mirror Groups

Ethics Advisory Board

Partnership Mgt & Coordination




• Coordination Team

- Consist of the Coordinator and Coordinator deputies, the PAHW project manager(s), communication officer, financial assistants.
 - Communication, dissemination & exploitation: *tbd*
- This is the central body and will carry out the day-to-day operational management by supporting PAHW partners.
- Is also responsible for the active monitoring of the PAHW progress (KPI), data management and report preparation.

• Partnership Management Team


- Composed of the Coordination Team and all WP leaders.
- Is the forum to discuss details of the EUP AH&W progress, notably annual work plans and related resource utilization and to prepare the GovB meetings.
- Cannot be informed about call topics, or will be excluded from applying to that call.

Governing Board




- The **GovB** will be the highest strategic and decision making body to approve modifications of the **organization**, the **SRIA**, defining the **work programme** incl. the **open and internal calls** and **other activities**, and to **monitor** the possible outcome and the expected impact.
 - Strategic role **to ensure consistency and completeness** in the implementation of PAHW SRIA, among internal calls, the external open calls and the other activities.
 - It agrees on **domains** for the respective calls (not call topics!).
 - Is **independent** from the Call Board, to avoid conflict of interest.
 - It will select the proposals to be funded, based on the available budget.
- Composed of **authorities that represent the participating AH&W FO and RPO**; consisting of a **max. of two representatives per PAHW participating country**, and probably with additional representatives from certain actors e.g. EC, advisory and stakeholders organizations.
- GovB will regularly consult the Stakeholders Committee and /or the Scientific Advisory Board, e.g. to update the SRIA, when defining the high-level domains of the R&I calls.

The Call Boards




- The **CB** will be composed of **FO, RPO and/or Authorities**; its composition is **variable** and depends on the partners participating in the organization of a particular call.
- The CB oversees the **independent organization** by the **call office** of both external open, and internal R&I calls, i.e. from drafting the call text and the call topics, collecting pre- and full proposals, organization of the external independent evaluation and listing of project proposals for funding.
 - For **external open calls**, **FO** define the topics and oversee the call organization.
 - For **internal calls**, **RPO** define the topics; the Call Board is composed of some RPO (or a non-research unit), FO and authorities, and organize the call as for external calls.

General Assembly



- The **GenA** will be composed of all partners/beneficiaries of PAHW, **one representative per partner** (+ deputy).
- Will be yearly informed about the progress of PAHW and is the ultimate decision making body dealing with the **Grant Agreement** (i.e. change of beneficiaries). For other decisions the Governing Board will decide.
- The GenA will strive to reach consensus and if consensus cannot be reached, the GenA will vote on different options. GenA Quorum and voting arrangements will be elaborated on in the Consortium Agreement.

Other Boards



- **European Commission and its Steering Group** follow up PAHW according to the Horizon Europe criteria.
- **Ethics Advisory Board (EAB):** With the aim to comply with the European ethical and legal frameworks, independent, external experts will be appointed in charge of advising on and monitoring ethical/ legal (incl. conflict of interest)/ regulatory issues of the Partnership, of the Data Management Plan, as well as of the projects funded within Partnership.
- **Scientific Advisory Board (SAB):** The SAB is invited by the GovB or Call Board for giving input to the research strategy, for joint transnational calls or other activities. The SAB consists of international researchers from universities, international organizations, Ministries, RPO outside the PAHW or similar, with expertise in the fields of AH&W.
- The **Stakeholders Committee** is composed of representatives of all stakeholder organizations. They will regularly share their expertise, advice and recommendation for inclusion in the PAHW activities.

Examples of Domain

- See Operational Objectives
 - **OO1 (Surveillance)**: Optimize surveillance systems for AH and zoonotic infections; set up a EU wildlife network, create network ‘bio-informatics + epidemiology’; monitor pathogens of veterinary importance and their AMR profiles; build networks and develop FAIR data; create a EU platform on animal welfare.
 - Probably, **calls are not strictly needed**
 - Partners can set up the networks (wildlife, bio-informatics + epidemiology, on FAIR data, AW) and produce foresight studies, to identify specific needs.
 - Surveillance systems for AH and for AMR in animal pathogens can be done internally
 - **OO2 (Diagnostics)**: Gain knowledge on priority pathogens; develop direct and indirect tools, tools for rapid detection, pen-site test; tools to distinguish infected and vaccinated individuals, dead and infectious pathogens, inter-species circulation; quantitative and multi-target diagnostics; non or less invasive and more convenient sample collection methods; new methodologies.
 - Mainly **both external open and internal calls**: suggested domain = “Diagnostics of AID”

EUP AH&W Strategic Research & Innovation Agenda



Collaboration with ICRAD

- ERA-NET [ICRAD](#): International Coordination of Research on Infectious Animal Diseases
- Plus extra input to cover Animal Welfare
- SRIA PAHW needs to comply with the EU criteria, i.e.
 - Well developed **intervention logic** + defined **timeframe** + **resources** + portfolio of activities
 - **Monitoring framework** for assessing the progress towards the objectives, incl. **KPI**
 - Identification of **other European Partnerships** with which to establish a formal and regular collaboration, as well as synergies with other EU, national or regional **initiatives**
 - **Plans for updating the SRIA**, including future possible involvement and consultations of stakeholders
- SRIA will be built based on the WG reports + ICRAD survey

Collaboration with ICRAD

- An online [survey](#) was prepared by ICRAD
 - Based on **desk study** that identified research priorities in existing European and global strategic documents.
 - Animal health and animal welfare sections.
 - Various domains: Surveillance and monitoring, Diagnostic procedures and methodologies, Risk management, Farm management, Vaccines, interventions and treatments, Socio-economic; in line with PAHW Dossier (intervention logic).
 - Includes the **research topics** from PAHW Dossier.
 - Launched in week 14 February, final deadline will be mid-March.
 - **The objective is to identify research priorities, especially for the first 2 years**
 - Analysis by ICRAD ongoing; Focus Groups and broad consultation until the end of 2022
 - To develop EUP AH&W SRIA aligned with RTD criteria.

Next steps



Partnership Animal Health & Welfare

- The preparatory PAHW Dossier was reviewed by RTD.G4; last (final) version is available on [EC web page](#).
- RTD contacted MS/AC mid March 2022; countries need to get prepared and committed (cash and in-kind) by the end of April 2022.
- In May 2022 will be known:
 - **Volume of commitment:** WG experts estimated €350M + about €50M organization.
 - **Ratio in kind vs cash:** if >1: higher probability for 50% EU co-funding.
- Then, further drafting of SRIA in collaboration with ICRAD and the 4 working groups before summer; consultation process of stakeholders until end 2022.

